Crunching the numbers for IMVT... Refresh in a moment for the full analysis.
Immunovant, Inc. (IMVT)
Healthcare
weak
$24.5
Updated: 2026-04-12
44
TradeApes Score
reduce
Financial Strength
50
Mixed
Operating Trend
40
Weak
Valuation
40
Weak
Capital Allocation
30
Weak
Risk
65
Healthy
Key Findings
+
Strong liquidity — current assets more than 2× current liabilities
−
Significant dilution — share count up more than 5% year over year
See the full analysis
Quarterly financials, DCF valuation model, Watchlist, and Stock Screener.
Create Free Account
Scores and valuations are model outputs, not investment advice. TradeApes does not provide financial, tax, or investment advice.